The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
about
Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.CT-P10 (Truxima™): A Rituximab Biosimilar.Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.The role of biosimilars in value-based oncology care
P2860
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The Rituximab Biosimilar CT-P1 ...... lysis in 28 European Countries
@ast
The Rituximab Biosimilar CT-P1 ...... lysis in 28 European Countries
@en
type
label
The Rituximab Biosimilar CT-P1 ...... lysis in 28 European Countries
@ast
The Rituximab Biosimilar CT-P1 ...... lysis in 28 European Countries
@en
prefLabel
The Rituximab Biosimilar CT-P1 ...... lysis in 28 European Countries
@ast
The Rituximab Biosimilar CT-P1 ...... lysis in 28 European Countries
@en
P2093
P2860
P1433
P1476
The Rituximab Biosimilar CT-P1 ...... lysis in 28 European Countries
@en
P2093
Fanni Rencz
László Gulácsi
Márta Péntek
Petra Baji
Valentin Brodszky
P2860
P2888
P304
P356
10.1007/S12325-017-0522-Y
P407
P577
2017-04-10T00:00:00Z
P6179
1084765384